"Rational hope" in the early treatment of Parkinson's disease

1999 ◽  
Vol 77 (6) ◽  
pp. 375-382 ◽  
Author(s):  
Theodore L Sourkes
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Drug Treatment ◽  
Early Treatment ◽  
Original Description ◽  
Anticholinergic Drugs ◽  
The Past ◽  
Modes Of Action

The drug treatment of Parkinson's disease since the original description of the malady in 1817 is described. Consideration is given to the historic use of alkaloids of the belladonna, harmala, and aporphine families, and of amphetamine. The introduction of the L-dopa treatment is described. The modes of action of the various drugs employed in the past as well as those in current use are described in the context of knowledge of the functioning of the nigrostriatal tract.Key words: anticholinergic drugs, apomorphine, bulbocapnine, L-dopa, harmine.

scholarly journals The drug treatment of parkinson’s disease

1984 ◽  
Vol 22 (10) ◽  
pp. 37-40
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Drug Treatment ◽  
Dopamine Agonist ◽  
Monoamine Oxidase B ◽  
Anticholinergic Drugs ◽  
Decarboxylase Inhibitor ◽  
Progressive Degeneration ◽  
The Brain

The symptoms of idiopathic Parkinson’s disease are due mainly to progressive degeneration of the dopaminergic nigro-striatal pathways in the brain. The drugs which can help fall into five categories: dopamine replacement, using dopa with a decarboxylase inhibitor; a dopamine agonist, bromocriptine;1 selegiline, recently introduced, which inhibits monoamine oxidase B; anticholinergic drugs; and amantadine.2 This article discusses recent ideas about the management of Parkinson’s disease, particularly about levodopa dosage, bromocriptine and selegiline.

Costs of drug treatment in Parkinson's disease

1998 ◽  
Vol 13 (2) ◽  
pp. 249-254 ◽  
Author(s):  
Richard C. Dodel ◽  
Karla M. Eggert ◽  
Marika S. Singer ◽  
Tobias E. Eichhorn ◽  
Oliver Pogarell ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Drug Treatment

scholarly journals Treatment of Early Parkinson's Disease

1999 ◽  
Vol 26 (S2) ◽  
pp. S39-S44 ◽  
Author(s):  
David A. Grimes ◽  
Anthony E. Lang
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Early Treatment ◽  
Dopaminergic Neurons ◽  
Symptomatic Therapy ◽  
Potential Toxicity ◽  
Significant Disability ◽  
Early Parkinson’S Disease

The early treatment of Parkinson's disease continues to be controversial as our understanding of the etiology of the disease remains incomplete. Ideally an intervention that reverses or protects against further damage to dopaminergic neurons would be initiated once the symptoms of the disease are recognized. Unfortunately, there are no currently available therapies that have been shown to have a major impact on the progression of the disease. However, delaying effective symptomatic therapy beyond a point of significant disability does result in increased mortality. Concerns have been raised regarding the potential toxicity of levodopa on remaining nigral neurons. Although there is little support for this concept, levodopa is associated with important complications. The development of new symptomatic treatments has made the management of early Parkinson's disease even more complex and requires that many different factors be considered prior to initiating therapy in an attempt to minimize current and future disability caused by the disease and its treatment.

scholarly journals Parkinson's Disease Management: Towards a New Paradigm

1999 ◽  
Vol 26 (S2) ◽  
pp. S53-S57 ◽  
Author(s):  
Mark Guttman ◽  
Oksana Suchowersky
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Surgical Treatment ◽  
Disease Management ◽  
Management Strategy ◽  
Clinical Symptoms ◽  
Treatment Modalities ◽  
New Paradigm ◽  
The Past

Over the past decade, management of Parkinson's disease has changed significantly due to the expansion of medical and surgical treatment modalities. Neurologists now have the ability (and the challenge) of choosing from multiple medications to devise an individual management strategy for each patient depending on his/her clinical symptoms and needs. Several different surgical therapies are also available. The topics covered in this supplement have highlighted the new options that are now available, as well as the treatments that have been in clinical usage. This review attempts to synthesize the information that is currently available in an attempt to help clinical neurologists make the appropriate choice for their patients.

Possibilities of non-drug treatment for Parkinson’s disease

2016 ◽  
Vol 116 (8) ◽  
pp. 22
Author(s):  
D. V. Pokhabov ◽  
V. G. Abramov ◽  
D. D. Pokhabov
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Drug Treatment

scholarly journals The Benefits of Humanized Yeast Models to Study Parkinson’s Disease

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
V. Franssens ◽  
T. Bynens ◽  
J. Van den Brande ◽  
K. Vandermeeren ◽  
M. Verduyckt ◽  
...  
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Molecular Mechanisms ◽  
Baker’S Yeast ◽  
Baker's Yeast ◽  
Pathogenic Role ◽  
The Past ◽  
Human Proteins

Over the past decade, the baker’s yeastSaccharomyces cerevisiaehas proven to be a useful model system to investigate fundamental questions concerning the pathogenic role of human proteins in neurodegenerative diseases such as Parkinson’s disease (PD). These so-called humanized yeast models for PD initially focused onα-synuclein, which plays a key role in the etiology of PD. Upon expression of this human protein in the baker’s yeastSaccharomyces cerevisiae, the events leading to aggregation and the molecular mechanisms that result in cellular toxicity are faithfully reproduced. More recently, a similar model to study the presumed pathobiology of theα-synuclein interaction partner synphilin-1 has been established. In this review we will discuss recent advances using these humanized yeast models, pointing to new roles for cell wall integrity signaling, Ca2+homeostasis, mitophagy, and the cytoskeleton.

Motor Profile and Drug Treatment of Nursing Home Residents with Parkinson's Disease

2012 ◽  
Vol 60 (12) ◽  
pp. 2277-2282 ◽  
Author(s):  
Nico J. Weerkamp ◽  
Sytse U. Zuidema ◽  
Gerrit Tissingh ◽  
Petra J. E. Poels ◽  
Marten Munneke ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nursing Home ◽  
Drug Treatment ◽  
Nursing Home Residents
Sign in / Sign up

Export Citation Format

Share Document